High bone turnover but normal bone mineral density in women suffering from schizophrenia

Psychological Medicine

Volumn 38, Issue 8, 2008, Pages 1195-1201

  Bergemann, N ^a   Parzer, P ^a   Mundt, C ^a   Auler, B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

17 oestradiol; Bone mineral density; Bone turnover; Intact parathyroid hormone; Osteocalcin; Schizophrenia

Indexed keywords

25 HYDROXYVITAMIN D; BENPERIDOL; BROMPERIDOL; CHLORPROTHIXENE; CLOPENTHIXOL; CLOZAPINE; DEOXYPYRIDINOLINE; ESTRADIOL; FLUPENTIXOL; FLUPHENAZINE; FOLLITROPIN; GONADOTROPIN DERIVATIVE; LEVOMEPROMAZINE; LUTEINIZING HORMONE; OLANZAPINE; OSTEOCALCIN; PARATHYROID HORMONE; PERPHENAZINE; PIPAMPERONE; PRASTERONE; PRASTERONE SULFATE; PROLACTIN; PROMETHAZINE; PROTHIPENDYL; PYRIDINOLINE; RISPERIDONE; SEX HORMONE; SULPIRIDE; TESTOSTERONE; ZOTEPINE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN BLOOD LEVEL; FEMALE; FEMUR NECK; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; LABORATORY TEST; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENSTRUATION; OSSIFICATION; OSTEOLYSIS; PREMENOPAUSE; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; URINE LEVEL; VITAMIN BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ESTRADIOL; FEMALE; HUMANS; LIGHT; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; PARATHYROID HORMONE; SCHIZOPHRENIA; TESTOSTERONE; VITAMIN D;

EID: 46749135677     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S003329170800319X     Document Type: Article

References (50)

1. Abraham G, Friedman RH, Verghese C (1996). Osteoporosis demonstrated by dual energy X-ray absorptiometry in chronic schizophrenic patients. Biological Psychiatry 40, 430-431.
2. Abraham G, Friedman RH, Verghese C, de Leon J (1995). Osteoporosis and schizophrenia: can we limit known risk factors? Biological Psychiatry 38, 131-132.
3. Abraham G, Halbreich U, Friedman RH, Josiassen RC (2002). Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophrenia Research 59, 17-18.
4. Abraham G, Paing WW, Kaminski J, Joseph A, Kohegy E, Josiassen RC (2003). Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. American Journal of Psychiatry 160, 1618-1620.
5. Al-Adwani A (1997). Neuroleptics and bone mineral density. American Journal of Psychiatry 154, 1173.
6. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. American Psychiatric Press: Washington, DC.
7. Baastrup PC, Christiansen C, Transbol I (1980). Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology 6, 56-59.
8. Basci K, Kosa JP, Borgulya G, Balla B, Lazary A, Nagy Z, Horvath C, Speer G, Lakatos P (2007). CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women. Calcified Tissue International 80, 154-159.
9. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M (2003). Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. Journal of Clinical Psychiatry 64, 761-766.
10. Bergemann N, Mundt C, Parzer P, Nagl I, Eckstein-Mannsperger U, Haisch S, Salbach B, Runnebaum B, Resch F (2005). Plasma concentration of estradiol in women suffering from schizophrenia treated with conventional and atypical antipsychotics. Schizophrenia Research 73, 357-366.
11. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C (2007). Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychological Medicine 37, 1427-1436.
12. Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M, Tan U (2002). Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. International Journal of Neuroscience 112, 817-828.
13. Delva NJ, Crammer JL, Jarzylo SV, Lawson JS, Owen JA, Sribney M, Weir BJ, Yendt ER (1989). Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biological Psychiatry 26, 781-793.
14. Erler K (1998). Elecsys immunoassay systems using electrochemiluminescence detection. Wiener Klinische Wochenschrift 110 (Suppl. 3), 5-9.
15. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G (2002). Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 58, 1348-1353.
16. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA (2000). Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Experimental and Clinical Endocrinology and Diabetes 108, 37-43.
17. Fujimaki T, Kurabyashi T, Ootani T, Yamamoto Y, Yasuda M, Tanaka K (1994). A study on bone metabolism in women with hyperprolactinemia. Nippon Sanka Fujinka Gakkai Zasshi 46, 423-428.
18. Goff DC, Henderson DC, Amico E (1992). Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. American Journal of Psychiatry 149, 1189-1194.
19. Green AI, Brown WA (1988). Prolactin and neuroleptic drugs. Endocrinology and Metabolism Clinics of North America 17, 213-223.
20. Haddad PM, Wieck A (2004). Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs 64, 2291-2314.
21. Halbreich U, Palter S (1996). Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophrenia Bulletin 22, 447-454.
22. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R (1995). Decreased bone mineral density in medicated psychiatric patients. Psychosomatic Medicine 57, 485-491.
23. Higuchi T, Komoda T, Sugishita M, Yamazaki J, Miura M, Sakagishi Y, Yamauchi T (1987). Certain neuroleptics reduce bone mineralization in schizophrenic patients. Neuropsychobiology 18, 185-188.
24. Howes OD, Wheeler MJ, Meaney AM, O'Keane V, Fogelman I, Blake G, Murray RM, Smith S (2005). Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. Journal of Clinical Psychopharmacology 25, 259-261.
25. Hummer M, Huber J (2004). Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Current Medical Research and Opinion 20, 189-197.
26. Huston BK, Bloom LJ (1975). Constitutional factors, stature, and chronic schizophrenia. Journal of Clinical Psychology 31, 26-29.
27. Kasperk C, Fitzsimmons R, Strong D, Mohann S, Jennings J, Wergedal J, Baylink D (1990). Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. Journal of Clinical Endocrinology and Metabolism 71, 1322-1329.
28. Keely EJ, Reiss JP, Drinkwater DT, Faiman C (1997). Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men. Endocrine Practice 3, 209-213.
29. Lindholm J, Steiniche T, Rasmussen E, Thamsborg G, Nielsen IO, Brockstedt-Rasmussen H (1991). Bone disorder in men with chronic alcoholism: a reversible disease? Journal of Clinical Endocrinology and Metabolism 73, 118-124.
30. Mak TW, Shek CC, Chow CC, Wing YK, Lee S (1998). Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. Journal of Clinical Endocrinology and Metabolism 83, 3857-3859.
31. Maric N, Popovic V, Jasovic-Gasic M, Pilipovic N, van Os J (2005). Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis. Schizophrenia Research 73, 351-355.
32. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80, 19-32.
33. Meaney AM, O'Keane V (2003). Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication. Journal of Psychopharmacology 17, 455-458.
34. Meaney AM, O'Keane V (2007). Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophrenia Research 93, 136-143.
35. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V (2004). Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. British Journal of Psychiatry 184, 503-508.
36. Misra M, Papakostas GI, Klibanski A (2004). Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. Journal of Clinical Psychiatry 65, 1607-1618.
37. Moniz C (1994). Alcohol and bone. British Medical Bulletin 50, 67-75.
38. Naidoo U, Goff DC, Klibanski A (2003). Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 28, 97-108.
39. O'Keane V, Meaney AM (2005). Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? Journal of Clinical Psychopharmacology 25, 26-31.
40. Petty RG (1999). Prolactin and antipsychotic medications: mechanism of action. Schizophrenia Research 35 (Suppl. 1), 67-73.
41. Plenge P, Rafaelsen O (1982). Lithium effects on calcium, magnesium and phosphate in man: effects on balance, bone mineral content, faecal and urinary excretion. Acta Psychiatrica Scandinavica 66, 361-373.
42. Poole KE, Reeve J (2005). Parathyroid hormone - a bone anabolic and catabolic agent. Current Opinion in Pharmacology 5, 612-617.
43. Pratt DA, Daniloff Y, Duncan A, Robins SP (1992). Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Analytical Biochemistry 207, 168-175.
44. Rogers GA, Burke GV (1987). Neuroleptics, prolactin, and osteoporosis. American Journal of Psychiatry 144, 388-389.
45. Seibel MJ (2003). Biochemical markers of bone metabolism in the assessment of osteoporosis: useful or not? Journal of Endocrinological Investigation 26, 464-471.
46. Seibel MJ, Baylink DJ, Farley JR, Epstein S, Yamauchi M, Eastell R, Pols HAP, Raisz LG, Gundberg CM (1997). Basic science and clinical utility of biochemical markers of bone turnover - a congress report. Experimental and Clinical Endocrinology and Diabetes 105, 125-133.
47. Seibel MJ, Woitge HW (1999). Basic principles and clinical applications of biochemical markers of bone metabolism. Biochemical and technical aspects. Journal of Clinical Densitometry 2, 299-321.
48. Sheth RD, Wesolowski CA, Jacob JC, Penney S, Hobbs JE, Bodensteiner JB (1995). Effect of carbamazepine and valproate on bone mineral density. Journal of Pediatrics 127, 256-262.
49. Slemenda CW (1994). Cigarettes and the skeleton. New England Journal of Medicine 330, 430-431.
50. WHO (1993). The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. World Health Organization: Geneva.